EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSDLAG00005023792
Gene Symbol: GABRG3
1 Cross references
223 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSDLAG00005009342
Gene Symbol: GLP2R
1 Cross references
204 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSDLAG00005020548
Gene Symbol: GRIA2
1 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSDLAG00005023538
Gene Symbol: GRIK1
1 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSDLAG00005018623
Gene Symbol: GRIK2
1 Cross references
243 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSDLAG00005009845
Gene Symbol: GRIK3
1 Cross references
257 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSDLAG00005007100
Gene Symbol: GRIA1A
1 Cross references
252 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1a

Ensembl ID : ENSDLAG00005034507
Gene Symbol: GRIN1A
1 Cross references
203 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSDLAG00005011378
Gene Symbol: GRIN2BB
1 Cross references
256 Possible Orthologues:

Glutamate Receptor, Metabotropic 2b

Ensembl ID : ENSDLAG00005023208
Gene Symbol: GRM2B
2 Cross references
210 Possible Orthologues:

Glutamate Receptor, Metabotropic 3

Ensembl ID : ENSDLAG00005023922
Gene Symbol: GRM3
1 Cross references
212 Possible Orthologues:

Glutamate Receptor, Metabotropic 5a

Ensembl ID : ENSDLAG00005017735
Gene Symbol: GRM5A
1 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).